51. Precision medicine integrating whole-genome sequencing, comprehensive metabolomics, and advanced imaging
- Author
-
Michael Doney, Ying-Chen Claire Hou, Pamila Brar, Bradley A. Perkins, Emily Y. Smith, Lori A. Napier, Christina Rybak, David S. Karow, C. Thomas Caskey, Weizhong Li, Keegan Duchicela, Saints Dominguez, Robyn Heister, Natalie M. Schenker-Ahmed, Richard J. Martin, Andrew M. Kahn, J. Craig Venter, Haibao Tang, Hung-Chun Yu, Christine Leon Swisher, Thomas J. Jönsson, Elizabeth T. Cirulli, Michael Hicks, Ewen F. Kirkness, Jaime Barea, Isaac V. Cohen, and Nathaniel Hernandez
- Subjects
Adult ,Diagnostic Imaging ,Male ,0301 basic medicine ,Genotype ,Heart Diseases ,precision medicine ,deep phenotyping ,Genomics ,030204 cardiovascular system & hematology ,Bioinformatics ,DNA sequencing ,Cohort Studies ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Genotype-phenotype distinction ,Genetics ,genomics ,Humans ,Medicine ,Genetic Predisposition to Disease ,Medical history ,Aged ,Aged, 80 and over ,Whole genome sequencing ,Multidisciplinary ,Whole Genome Sequencing ,advanced imaging ,business.industry ,Heterozygote advantage ,Biological Sciences ,Middle Aged ,Precision medicine ,metabolomics ,Phenotype ,030104 developmental biology ,PNAS Plus ,Female ,business - Abstract
Significance To understand the value and clinical impact of surveying genome-wide disease-causing genes and variants, we used a prospective cohort study design that enrolled volunteers who agreed to have their whole genome sequenced and to participate in deep phenotyping using clinical laboratory tests, metabolomics technologies, and advanced noninvasive imaging. The genomic results are integrated with the phenotype results. Approximately 1 in 6 adult individuals (17.3%) had genetic findings and, when integrated with deep phenotyping data, including family/medical histories with genetic findings, 1 in 9 (11.5%) had genotype and phenotype associations. Genomics and metabolomics association analysis revealed 5.1% of heterozygotes with phenotype manifestations affecting serum metabolite levels. We report observations from our study in which health outcomes and benefits were not measured., Genome sequencing has established clinical utility for rare disease diagnosis. While increasing numbers of individuals have undergone elective genome sequencing, a comprehensive study surveying genome-wide disease-associated genes in adults with deep phenotyping has not been reported. Here we report the results of a 3-y precision medicine study with a goal to integrate whole-genome sequencing with deep phenotyping. A cohort of 1,190 adult participants (402 female [33.8%]; mean age, 54 y [range 20 to 89+]; 70.6% European) had whole-genome sequencing, and were deeply phenotyped using metabolomics, advanced imaging, and clinical laboratory tests in addition to family/medical history. Of 1,190 adults, 206 (17.3%) had at least 1 genetic variant with pathogenic (P) or likely pathogenic (LP) assessment that suggests a predisposition of genetic risk. A multidisciplinary clinical team reviewed all reportable findings for the assessment of genotype and phenotype associations, and 137 (11.5%) had genotype and phenotype associations. A high percentage of genotype and phenotype associations (>75%) was observed for dyslipidemia (n = 24), cardiomyopathy, arrhythmia, and other cardiac diseases (n = 42), and diabetes and endocrine diseases (n = 17). A lack of genotype and phenotype associations, a potential burden for patient care, was observed in 69 (5.8%) individuals with P/LP variants. Genomics and metabolomics associations identified 61 (5.1%) heterozygotes with phenotype manifestations affecting serum metabolite levels in amino acid, lipid and cofactor, and vitamin pathways. Our descriptive analysis provides results on the integration of whole-genome sequencing and deep phenotyping for clinical assessments in adults.
- Published
- 2020